Storia in 10 fonti

Correction to Novartis Article

Novartis will pay up to $400 million in potential additional payments. "Novartis to Buy Myricx Bio for Up to $1.5 Billion," at 0523 GMT, misstated the figure.

Raccontata da

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

morningstar.comStai leggendo1 mese fa

Correction to Novartis Article

Novartis will pay up to $400 million in potential additional payments. "Novartis to Buy Myricx Bio for Up to $1.5 Billion," at 0523 GMT, misstated the figure.

originale

Timeline cronologica

lunedì 6 luglio 2026·biopharmadive.com
Novartis to acquire ADC developer in a deal worth up to $1.5B
The deal hands over two ADCs with a different mechanism of action targeting cell growth, and marks Novartis' entry into ADC development.
lunedì 6 luglio 2026·afr.com
Aussie super funds hit the jackpot in $2b UK biotech deal
Brandon Capital will receive more than $300 million from the sale of Myricx, which is developing cancer-killing “biological missiles”, to Swiss giant Novartis.

Correction to Novartis Article

Confronto fonti

Correction to Novartis Article

Timeline cronologica

Novartis to acquire ADC developer in a deal worth up to $1.5B

Aussie super funds hit the jackpot in $2b UK biotech deal

Novartis buys UK biotech Myricx for up to $1.5bn to chase a new cancer-drug class

Novartis commits $1.1B upfront to take Myricx Bio and its next-gen ADC platform

Novartis acquires British start-up Myricx Bio

Patent cliff fuels Novartis' $1.5bn swoop for London biotech

Novartis Scoops up UK Biotech Myricx in $1.5 Billion Cancer Push - Novartis (NYSE:NVS)

Correction to Novartis Article

Novartis: rileva gruppo biotecnologie Myricx Bio per 1,1 mld $

Novartis buys UK biotech Myricx for up to $1.5bn to chase a new cancer-drug class

London's Myricx Bio lands up to $1.5B Novartis exit after raising just $121M — TFN

Novartis acquires British start-up Myricx Bio

Novartis commits $1.1B upfront to take Myricx Bio and its next-gen ADC platform

Novartis rileva Myricx Bio in un’operazione fino a 1,5 miliardi di dollari

Novartis Scoops up UK Biotech Myricx in $1.5 Billion Cancer Push - Novartis (NYSE:NVS)

Patent cliff fuels Novartis' $1.5bn swoop for London biotech